And Platinum Pharma and its partners announced a partnership with Kidis Pharma to develop monoclonal antibodies, natural killer cell therapy COVID-19.

Guide: The research will be carried out for the treatment of new coronavirus pneumonia, further expand and platinum medicine in the field of new coronavirus antibodies.
CAMBRIDGE, Mass., Rotterdam, Netherlands, and Suzhou, China August 19, 2020 /USC/-- AND PLATINUM Pharmaceuticals (HBM) and its partners Utrecht University, Erasmus Medical Center and Viviclinics-DDL announced today that they are working with Kidis Pharma (Amsterdam and Brussels Euron european stock exchanges) KDS) collaborated on a joint therapy for antibody (mAb) and natural killer (NK) cells, which will further expand and platinum medicine's research in the field of new coronavirus (SARS-CoV-2) antibodies for the treatment of new coronavirus pneumonia (COVID-19).
details of the cooperation have not been disclosed.
, based on and Platinum Pharma's strategy for developing a family of products for the new coronavigic virus, announced in June 2020 that it had established a strategic partnership with Utrecht University and Erasmus Medical Center to develop the project in partnership with international pharmaceutical giant AbbVie.
this collaboration is based on an early research project with proven SARS-CoV-2 activity in Platinum Pharma and Kiadis' K-NK cell therapy platform.
studies have confirmed that COVID-19 destroys the immunity of NK cells, so coVID-19 patients lack normal NK cells.
and Platinum Pharmaceuticals and their partners studied all-human, non-blocking antibodies 49F1 targeting conservative areas of the new coronavirus S protein, and in-body studies have shown that the antibody has a strong affinity for binding to two coronaviruses, SARS-CoV-2 and SARS-CoV.
study will examine the elimination of K-NK cells from SARS-CoV-2 virus and infected cells, as well as the synergy between antibodies and NK cells.
NK cells are the immune system's first line of defense against tumor cells and infectious diseases.
K-NK-ID101 cells have the potential to enhance antiviral activity and prevent inflammation from worsening, so it has good therapeutic prospects for repairing the problem of lack of normal NK cells.
the properties of K-NK-ID101 cells that can be produced on a large scale and can be frozen, it is expected to reach patients worldwide quickly.
" innovative collaboration with Kiadis provides us with an opportunity to explore potential synergies between congenital and adaptive immunity. Dr. Jinsong Wang, founder, chairman and chief executive officer of
and Platinum Pharmaceuticals, said, "This partnership is a reflection of the multi-pronged approach taken by Platinum Pharmaceuticals and partners to accelerate the development of new human antibodies in response to the current epidemic of new crowns, as well as the company's ability to take full advantage of the All-Human Antibody Genetically Modified Mouse Platform (HarbourMic®) and its own next-generation technologies."
.